NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Real-time Estimate Cboe BZX Other stock markets 11:57:12 2025-07-14 am EDT			5-day change	1st Jan Change
17.48 ^USD	-0.65%		+3.70%	-41.22%

Jul. 08	Ladenburg Thalmann Initiates NovoCure at Buy With $30 Price Target	MT
Jul. 01	Novocure to Present Final Secondary Endpoint Data from the Phase 3 Panova-3 Trial of Tumor Treating Fields in Pancreatic Cancer At the Esmo Gastrointestinal Cancers Congress 2025	CI

NovoCure Limited - Special Call

Published on 05/31/2025 at 23:20, updated on 06/02/2025 at 16:52

Presenter Speech
William Doyle (Executives)

Hello. Good evening, everyone. Welcome to Chicago, welcome to ASCO, and welcome to Novocure's post-PANOVA-3 investor event. It's my great pleasure to host

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about NovoCure Limited

Ladenburg Thalmann Initiates NovoCure at Buy With $30 Price Target	Jul. 08	MT
Novocure to Present Final Secondary Endpoint Data from the Phase 3 Panova-3 Trial of Tumor Treating Fields in Pancreatic Cancer At the Esmo Gastrointestinal Cancers Congress 2025	Jul. 01	CI
Novocure Insider Sold Shares Worth $528,413, According to a Recent SEC Filing	Jun. 04	MT
NovoCure Limited - Special Call	Jun. 02
Zai Lab and Novocure Announce Results from the Phase 3 Panova-3 Trial of Tumor Treating Fields Therapy for Pancreatic Cancer to Be Presented At 2025 Asco Annual Meeting	May. 31	CI
Novocure Says Ttfields Therapy Shows Significant Improvement In Overall Survival For Pancreatic Cancer	May. 31	RE
Novocure Announces Results from the Phase 3 Panova-3 Trial of Novocure's Tumor Treating Fields Therapy for Pancreatic Cancer to Be Presented At 2025 ASCO Annual Meeting	May. 31	CI
Novocure Announces Upcoming Investor Events	May. 27	RE
NovoCure's Q1 Loss Narrows, Revenue Rises	Apr. 24	MT
NovoCure Limited, Q1 2025 Earnings Call, Apr 24, 2025	Apr. 24
Earnings Flash (NVCR) NOVOCURE Posts Q1 Revenue $155M, vs. FactSet Est of $146.9M	Apr. 24	MT
Earnings Flash (NVCR) NOVOCURE Posts Q1 Loss $-0.31 Per Share, vs. FactSet Est of $-0.46	Apr. 24	MT
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 24	CI
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of Its Tumor Treating Fields Therapy for Pancreatic Cancer as A Late-Breaking Oral Presentation At the 2025 ASCO Annual Meeting	Apr. 23	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Apr. 22	MT
NovoCure Says Optune Lua Device Gets CE Mark to Treat Lung Cancer	Apr. 22	MT
Novocure'S Optune Lua® Receives CE Mark Approval	Apr. 22	RE
Novocure Insider Sold Shares Worth $266,126, According to a Recent SEC Filing	Mar. 03	MT
Novocure Insider Sold Shares Worth $296,257, According to a Recent SEC Filing	Mar. 03	MT
NovoCure's Q4 Loss Widens, Revenue Rises	Feb. 27	MT
NovoCure Limited, Q4 2024 Earnings Call, Feb 27, 2025	Feb. 27
Earnings Flash (NVCR) NOVOCURE Reports Q4 Revenue $161.3M, vs. FactSet Est of $161.3M	Feb. 27	MT
NovoCure Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	Feb. 27	CI
NovoCure Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Feb. 27	CI
C Worldwide Healthcare Select up 5.8% in January - divests Illumina	Feb. 12	FW